Detalhe da pesquisa
1.
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
N Engl J Med
; 385(23): 2150-2160, 2021 12 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34449183
2.
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Circulation
; 143(7): 673-684, 2021 02 16.
Artigo
Inglês
| MEDLINE | ID: mdl-33587659
3.
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups.
Am Heart J
; 247: 24-32, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34990581
4.
Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial.
Europace
; 24(11): 1730-1738, 2022 11 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36017608
5.
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.
Eur Heart J
; 42(17): 1698-1706, 2021 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33760027
6.
Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study.
Am Heart J
; 235: 132-139, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33493453
7.
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
Europace
; 23(1): 65-72, 2021 01 27.
Artigo
Inglês
| MEDLINE | ID: mdl-33249467
8.
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Circulation
; 140(22): 1792-1801, 2019 11 26.
Artigo
Inglês
| MEDLINE | ID: mdl-31597460
9.
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Circulation
; 139(6): 760-771, 2019 02 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30586727
10.
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
Eur Heart J
; 40(19): 1541-1550, 2019 05 14.
Artigo
Inglês
| MEDLINE | ID: mdl-30624719
11.
Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.
Europace
; 21(2): 306-312, 2019 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30462220
12.
Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
Am Heart J
; 196: 105-112, 2018 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29421002
13.
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Circulation
; 131(1): 82-90, 2015 Jan 06.
Artigo
Inglês
| MEDLINE | ID: mdl-25403645
14.
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
Vasc Med
; 21(4): 361-8, 2016 08.
Artigo
Inglês
| MEDLINE | ID: mdl-27165711
15.
Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.
Crit Care
; 20(1): 273, 2016 Sep 23.
Artigo
Inglês
| MEDLINE | ID: mdl-27659071
16.
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Am Heart J
; 169(5): 597-604.e5, 2015 May.
Artigo
Inglês
| MEDLINE | ID: mdl-25965706
17.
Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation.
Eur J Heart Fail
; 25(6): 832-841, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36987929
18.
Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes.
JACC Clin Electrophysiol
; 9(4): 569-580, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-37100536
19.
Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min.
Clin Pharmacol Drug Dev
; 11(5): 666-674, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34877813
20.
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
Eur Heart J Cardiovasc Pharmacother
; 8(7): 695-706, 2022 Sep 29.
Artigo
Inglês
| MEDLINE | ID: mdl-34962979